Report #2863549

Received Oct 6, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Male
Age: 83 yrs
State: IL
Recovered: Unknown
Vaccinated: Jun 24, 2025
Onset: Jun 24, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	3273H	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

Late 2nd dose; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 83-year-old male patient who received Herpes zoster (Shingrix) (batch number 3273H, expiry date 31-MAR-2027) for prophylaxis. Previously administered products included Shingrix (received first dose on 28 Dec 2020 batch lot CE4DE). On 24-JUN-2025, the patient received the 2nd dose of Shingrix. On 24-JUN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: Late 2nd dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 01-OCT-2025 The patient who got the first dose of Shingrix on 28Dec 2020, 2nd dose on 24 Jun 2025. However, the patient did not remember getting the 1st dose but pharmacy in the shows he got the first dose.